The Ministry of Industry and Trade reported that several domestic companies are working on an analog of the American drug "Zepatir" against hepatitis C.
The drug "Zepatir" is under patent in the Russian Federation until March 2030. According to operational information, several domestic companies are developing a reproduced pharmaceutical drug.
Earlier, Kommersant reported that the American MSD has decided to stop supplying "Zepatir" to Russia. But it is one of the most demanded drugs, which accounts for almost 20% of all state drug purchases for this disease. And although there are other drugs against hepatitis C in Russia, "Zepatir" is one of the most affordable and effective. Therefore, the appearance of a domestic analogue is extremely important.
To support the creation of demanded analogs of medicinal products from the list of vitally necessary ones, but under patent protection, from 2023, the "products on the shelf" mechanism is being introduced. According to it, Russian companies will receive subsidies on a competitive basis for the development and registration of patented drugs for medical use in Russia.
The Ministry of Health has reported that the Russian company "R-Pharm" has a sufficient supply of "Zepatir" – there will be enough of the drug until 2025.
To remind, yesterday in Moscow, a modern pharmaceutical production with a capacity of 270 million packages of drugs per year, was opened.